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1. Introduction
In Alzheimer’s disease (AD), β-amyloid deposition and neu-
rofibrillary tangles (NFTs), composed of hyperphosphorylated
tau fibrils, are considered to be major pathologic features. Evi-
dence from the genetic studies of familial AD has given rise to
the β-amyloid hypothesis in which β-amyloid is proposed as the
cause of AD; thus, the reduction of β-amyloid has been viewed
as a potential therapeutic target for AD.1 However, most studies
targeting β-amyloid have failed in phase III clinical trial, as
discussed extensively elsewhere.2 A major explanation for such
failures may be that such therapies have been tested in patients
with early- to mid-stage AD, when disease progression is
already relatively advanced. In fact, when first AD symptoms
are reported or detected, it seems that damage is irreversible and
not amenable to slowing down or blockade. Accordingly,
researchers are attempting to identify very early stages of
disease, that may be therapeutically targetable; that is, they are
now seeking an early window of therapeutic opportunity. Even
so, this approach depends on differentiating between the trigger
and the bullet in AD and their relationship to β-amyloid. At the
same time, researchers are becoming aware that an alternative
target for halting clinical progression, even in early to moderate
AD, may be necessary.
2. Tau executes neuronal loss and brain dysfunction
in AD
NFTs are the other pathologic hallmark of AD. Although
β-amyloid deposition is seen only in AD, NFTs are associated
with several neurodegenerative diseases, the so-called
tauopathies. Because all tauopathies are accompanied by NFTs
and neuronal dysfunction, NFTs are considered to be a
common pathologic marker for a range of neurologic disorders.
In these diseases, the rate of neuronal loss exceeds the occur-
rence of NFTs, suggesting that NFT formation and neuron
death share a common underlying mechanism.3,4 This hypoth-
esis is strongly supported by the discovery of a tau gene
mutation in patients with frontotemporal dementia with parkin-
sonism linked to chromosome 17 (FTDP-17).5–7 The FTDP-17-
associated tau gene mutation is the causal factor in FTDP-17, a
dementing disease characterized by NFT formation and neuron
loss. Analyses of mutated tau in FTDP-17 conclusively demon-
strated that tau dysfunction or abnormality alone induces the
neurodegeneration characterized by NFTs and neuronal death
that ultimately leads to clinical dementia.
3. Neuronal loss occurs in a process of tau fibril
formation
Mice that overexpress P301L mutant tau under the regula-
tion of a tetracycline-inducible promoter display age-related
NFTs, neuronal death, and behavioral deficits. Although inhi-
bition of mutant tau in these mice blocks neuronal death and
improves memory, NFTs continue to form.8–10 This suggests
that NFTs are not themselves toxic, but rather that the mecha-
nism of NFT formation is shared by the process underlying
neuronal death and neuronal dysfunction. To understand a
process of NFT formation that links with neuronal death, we
first need to know how monomeric tau forms fibrillar tau. To
track structural changes in tau in solution, and to understand the
relationship between different tau aggregates, Maeda and
colleagues11 investigated how tau assembly in vitro changes
over time by measuring thioflavin T fluorescence using atomic
force microscopy (AFM). As thioflavin T fluorescence
increases, 2 forms of tau aggregates can be observed with
AFM: a granular tau oligomer and a fibrillar tau aggregate.
Before forming fibrillar aggregates, tau forms 2 different
types of tau aggregate: oligomeric tau (sarkosyl-soluble, not
detectable by AFM) and granular oligomeric tau (sarkosyl-
insoluble, detectable under AFM). If NFTs represent tomb-
stones of neurodegeneration, these 2 kinds of intermediate tau
oligomer may play a role in synapse loss, neuron loss, and,
ultimately, the neurodegeneration typically seen in tauopathies
(Fig. 1).
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4. Tau aggregation inhibitor ameliorates neuronal loss in
P301L tau mouse model
Analysis of our P301L tau transgenic mouse model re-
vealed that neuronal loss and insoluble tau formation were
detected without formation of pathologically relevant NFTs.
Because P301L tau mice do not form tau fibrils but still
exhibit neuronal loss, we suggest that toxicity of tau aggre-
gates could be attributed to granular tau. For further testing of
this notion, we aimed to reduce formation of granular tau
oligomer by screening the chemical compound isoproterenol,
which associates with tau to inhibit granular tau formation.
Interestingly, oral administration of isoproterenol in our P301L
tau mice resulted in reduced neuronal loss accompanied by
inhibition of sarkosyl-insoluble tau level compared with vehicle
control.12 Altogether, our studies offer novel insights about tau
aggregation pathology, strongly suggesting that granular tau
oligomer represents a toxic tau aggregate whereas isoproter-
enol seems to be a promising compound for blocking AD
progression.
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Fig. 1. Before neurofibrillary tangle (NFT) formation, tau aggregates and forms tau oligomer and granular tau oligomer. Hyperphosphorylated tau and tau oligomers
are involved in synapse loss, and granular tau oligomer causes neuronal loss. Blocking granular tau oligomer formation results in inhibition of neuronal loss
accompanying ameliorated neuronal dysfunction in a mouse model.
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